Belantamab Mafodotin in the Treatment of Relapsed or Refractory Multiple Myeloma

Sheikh, Semira; Lebel, Eyal; Trudel, Suzanne

doi:10.2217/fon-2020-0521

Cited by 12 publications

(12 citation statements)

References 66 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Antibody-drug conjugates (ADCs), which connected mAbs with bioactive drugs through chemical linkers ( 36 ), can accurately identify tumor cells and exert high-efficiency cytotoxic effects on malignant cells without damaging healthy tissues ( 37 ). Belantamab mafodotin (GSK2857916), which is a microtubule-disrupt agent ( 38 ), consists of humanized BCMA-targeted IgG1 and monomethyl auristatin-F (MMAF).…”

Section: Progress Of Bcma-targeted Immunotherapiesmentioning

confidence: 99%

Targeting BCMA to Treat Multiple Myeloma: Updates From the 2021 ASH Annual Meeting

Guo

Zhang

et al. 2022

Front. Immunol.

View full text Add to dashboard Cite

With the gradual improvement of treatment regimens, the survival time of multiple myeloma (MM) patients has been significantly prolonged. Even so, MM is still a nightmare with an inferior prognosis. B-cell maturation antigen (BCMA) is highly expressed on the surface of malignant myeloma cells. For the past few years, significant progress has been made in various BCMA-targeted immunotherapies for treating patients with RRMM, including anti-BCMA mAbs, antibody-drug conjugates, bispecific T-cell engagers, and BCMA-targeted adoptive cell therapy like chimeric antigen receptor (CAR)-T cell. The 63rd annual meeting of the American Society of Hematology updated some information about the application of BCMA in MM. This review summarizes part of the related points presented at this conference.

show abstract

Section: Progress Of Bcma-targeted Immunotherapiesmentioning

confidence: 99%

Targeting BCMA to Treat Multiple Myeloma: Updates From the 2021 ASH Annual Meeting

Guo

Zhang

et al. 2022

Front. Immunol.

View full text Add to dashboard Cite

show abstract

“…Belantamab mafodotin (BM) is the first-in-class humanized afucosylated anti-BCMA IgG1 ADC, recently approved by the US Food and Drug Administration (FDA) for monotherapy in patients with relapsed or refractory MM (RRMM) [ 24 , 35 , 36 ]. Initial data in a multicenter phase I trial (DREAMM-1) in heavily pretreated (pronounced PIs and IMiDs) RRMM patients showed that BM (BMA117159) was effective with ORR of 60% (14% CR, 60% very good partial response (vgPR)) and PFS of 12 months [ 37 ] with a manageable side effects profile.…”

Section: Bmca-targeted Treatment In MMmentioning

confidence: 99%

BCMA in Multiple Myeloma—A Promising Key to Therapy

Kleber

Ntanasis‐Stathopoulos

Terpos

2021

JCM

View full text Add to dashboard Cite

Despite the discoveries of numerous agents including next generation proteasome inhibitors, immunomodulatory drugs, and monoclonal antibodies, multiple myeloma (MM) remains an incurable disease. The field of myeloma treatment in refractory or relapsed patients after standard therapy entered a new era due to the B-cell maturation antigen (BMCA) targeted approach. BCMA is a member of the tumor necrosis factor receptor family with high expression in mature B-lymphocytes and plasma cells. Given the understanding of BCMA mechanism of action in MM, BCMA plays a promising role as a therapeutic target. Several clinical trials are underway to evolve the current BCMA targeted treatment concept such as antibody-drug conjugates (ADCs), bispecific T cell engagers (BITEs) and chimeric antigen receptor (CAR) T cell therapy. Current results of representative BCMA trials may close the gap of the unmet clinical need to further improve the outcome of heavily pretreated MM patients with the potency to change the paradigm in newly diagnosed and refractory MM. This comprehensive review will give an update on various BMCA targeted treatment modalities (ADCs, BITEs, CAR T cell therapy) and its existing results on efficacy and safety from preclinical and clinical trials.

show abstract

“…The third one is the ICD (immunogenic cell death), through the expression of antigens specific to dying tumor cells. 65 …”

Section: “Old” Generation Immunotherapiesmentioning

confidence: 99%

Novel Experimental Drugs for Treatment of Multiple Myeloma

Offidani

Corvatta²,

Morè

et al. 2021

JEP

View full text Add to dashboard Cite

Multiple myeloma (MM) is the second most frequent hematological malignancy characterized by bone marrow aberrant plasma cells proliferation leading to a genetic complex and heterogeneous disease, with a median survival ranging from two to more than 10 years. By using new drugs such as proteasome inhibitors (PIs), immunomodulatory drugs (IMiDs), monoclonal antibodies (mAbs) in different combinations and high-dose therapy followed by auto-transplantation, there has been an amazing improvement in the outcome of this disease in recent years. Despite this, MM is still considered an incurable disease, characterized by remission periods alternated with relapse/progression episodes finally leading to resistant disease. In particular, patients who become refractory to PIs, IMiDs and mAbs have a very poor outcome. Moreover, to overcome resistant residual disease, a large combination of drugs will be increasingly used in early lines of therapy; this further reduces the therapeutic options at each relapse. This natural history means that MM always needs new drugs/strategies to overcome the incoming resistance. New combinations of naked mAbs are becoming the therapy of choice for patients refractory to lenalidomide and/or PI; conjugated mAbs will be useful in triple- and more-refractory patients; CAR-T cells and bispecific mAbs have shown relevant results in very advanced stages of disease. In this review, we reported the results of these new therapies and explored their potential applications. Personalized and precision medicine seem to be the new frontier of cancer treatment. Although no single or few factors have been identified as disease drivers in MM, recurrent gene mutations were recognized and specific compounds targeting these alterations were developed and studied. Therefore, we reviewed these targeted drugs to try to understand what the best therapeutic strategy in MM is.

show abstract

Belantamab Mafodotin in the Treatment of Relapsed or Refractory Multiple Myeloma

Cited by 12 publications

References 66 publications

Targeting BCMA to Treat Multiple Myeloma: Updates From the 2021 ASH Annual Meeting

Targeting BCMA to Treat Multiple Myeloma: Updates From the 2021 ASH Annual Meeting

BCMA in Multiple Myeloma—A Promising Key to Therapy

Novel Experimental Drugs for Treatment of Multiple Myeloma

Contact Info

Product

Resources

About